ABSTRACT
HHV-8 is an oncogenic Gammaherpesvirinae discovered in 1994 during the HIV pandemic. It is the causative agent of Kaposi's sarcoma, and is also associated with the occurrence of several aggressive B lymphoproliferative disorders. Most of them occur in an immunosuppression setting, usually due to HIV infection. Multicentric HHV8-associated Castleman's disease and KSHV Inflammatory Cytokine Syndrome (KICS) are primarily reactive entities with prominent systemic features. They illustrate the cytokinic storm induced by HHV-8 in its cell host. On the other hand, HHV-8 can drive proliferation and lymphomagenesis of its plasmablastic cell host, and is associated with a risk to develop aggressive lymphomas with plasmacytic differenciation. Primary effusion lymphoma usually localizes in body cavities and may affect other extra-nodal sites ; its prognostic is poor. Diffuse large B-cell lymphoma HHV-8, NOS affect more commonly nodes and blood and evolve from infected cell of HHV-8 associated Castleman disease. On the contrary, germinotropic lymphoproliferative disorders presents mainly as localized adenopathy with indolent course, and show polyclonality. Histology plays a key role in distinguishing these different entities and need expert reviewing, especially since they may be associated with each other. Besides lymphoproliferative disorders, HHV8 is associated with various hematological manifestations. The aim of this review is to provide an update on the presentation, diagnosis, and management of immunologic and hematologic complications associated with HHV-8.
Subject(s)
Castleman Disease , HIV Infections , Hematologic Diseases , Herpesvirus 8, Human , Lymphoproliferative Disorders , Sarcoma, Kaposi , Castleman Disease/diagnosis , Castleman Disease/epidemiology , Castleman Disease/therapy , Hematologic Diseases/diagnosis , Hematologic Diseases/epidemiology , Hematologic Diseases/etiology , Humans , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/pathology , Sarcoma, Kaposi/pathologyABSTRACT
Epstein-Barr virus (EBV), discovered in 1964, is a double-stranded DNA virus belonging to the Herpesviridae family. EBV has a lymphoid tropism with transforming capacities using different oncogenic viral proteins. This virus has two replication cycles: a lytic cycle mainly occuring during primary infection and a latent cycle allowing viral persistence into host memory B cells. More than 90% of adults are seropositive for EBV worldwide, with a past history of asymptomatic or mild primary infection. EBV infection can sometimes cause life-threatening complications such as hemophagocytic lymphohistiocytosis, and lead to the development of lymphoproliferative disorders or cancers. Risk factors associated with these phenotypes have been recently described through the study of monogenic primary immune deficiencies with EBV susceptibility. We here review the virological and immunological aspects of EBV infection and EBV-related complications with an overview of current available treatments.
Subject(s)
Epstein-Barr Virus Infections , Immunologic Deficiency Syndromes , Lymphohistiocytosis, Hemophagocytic , Lymphoproliferative Disorders , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/epidemiology , Herpesvirus 4, Human , Humans , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/epidemiologyABSTRACT
With combined antiretroviral therapy (cART), the risk for HIV-infected individuals to develop a non-Hodgkin lymphoma is diminished. However, the incidence of Burkitt lymphoma (BL) remains strikingly elevated. Most BL present a t(8;14) chromosomal translocation which must take place at a time of spatial proximity between the translocation partners. The two partner genes, MYC and IGH, were found colocalized only very rarely in the nuclei of normal peripheral blood B-cells examined using 3D-FISH while circulating B-cells from HIV-infected individuals whose exhibited consistently elevated levels of MYC-IGH colocalization. In vitro, incubating normal B-cells from healthy donors with a transcriptionally active form of the HIV-encoded Tat protein rapidly activated transcription of the nuclease-encoding RAG1 gene. This created DNA damage, including in the MYC gene locus which then moved towards the center of the nucleus where it sustainably colocalized with IGH up to 10-fold more frequently than in controls. In vivo, this could be sufficient to account for the elevated risk of BL-specific chromosomal translocations which would occur following DNA double strand breaks triggered by AID in secondary lymph nodes at the final stage of immunoglobulin gene maturation. New therapeutic attitudes can be envisioned to prevent BL in this high risk group.
Subject(s)
B-Lymphocytes/metabolism , Burkitt Lymphoma/genetics , Gene Products, tat/physiology , Genes, myc , Immunoglobulin Heavy Chains/genetics , Aged , Female , Humans , Male , Middle AgedSubject(s)
Abdominal Pain/chemically induced , Allium , Colchicine/poisoning , Diarrhea/chemically induced , Plant Poisoning/etiology , Vomiting/chemically induced , Abdominal Pain/diagnosis , Adult , Diagnosis, Differential , Diarrhea/diagnosis , Humans , Male , Plant Poisoning/diagnosis , Vomiting/diagnosisABSTRACT
Complement system is a part of innate immunity, its main function is to protect human from bacterial infection. As genetic disorders, complement deficiencies are often diagnosed in pediatric population. However, complement deficiencies can also be revealed in adults but have been poorly investigated. Herein, we describe a case series of infections revealing complement deficiency in adults to study clinical spectrum and management of complement deficiencies.A nationwide retrospective study was conducted in French university and general hospitals in departments of internal medicine, infectious diseases enrolling patients older than 15 years old who had presented at least one infection leading to a complement deficiency diagnosis.Forty-one patients included between 2002 and 2015 in 19 different departments were enrolled in this study. The male-to-female ratio was 1.3 and the mean age at diagnosis was 28â±â14 (15-67) years. The main clinical feature was Neisseria meningitidis meningitis 75% (nâ=â31/41) often involving rare serotype: Y (nâ=â9) and W 135 (nâ=â7). The main complement deficiency observed was the common final pathway deficiency 83% (nâ=â34/41). Half of the cohort displayed severe sepsis or septic shock at diagnosis (nâ=â22/41) but no patient died. No patient had family history of complement deficiency. The mean follow-up was 1.15â±â1.95 (0.1-10) years. Half of the patients had already suffered from at least one infection before diagnosis of complement deficiency: meningitis (nâ=â13), pneumonia (nâ=â4), fulminans purpura (nâ=â1), or recurrent otitis (nâ=â1). Near one-third (nâ=â10/39) had received prophylactic antibiotics (cotrimoxazole or penicillin) after diagnosis of complement deficiency. The vaccination coverage rate, at the end of the follow-up, for N meningitidis, Streptococcus pneumonia, and Haemophilius influenzae were, respectively, 90% (nâ=â33/37), 47% (nâ=â17/36), and 35% (nâ=â14/34).This large study emphasizes that complement deficiencies can be revealed in adults by infectious episodes. Most of them were meningococcal infections revealing common final pathway deficiency. To avoid undiagnosis or late diagnosis, adult displaying first episode of N meningitidis infection should be tested for complement deficiency.
Subject(s)
Bacterial Infections/immunology , Complement System Proteins/deficiency , Delayed Diagnosis , Adolescent , Adult , Age Factors , Aged , Bacterial Infections/drug therapy , Complement Membrane Attack Complex/deficiency , Female , France , Humans , Male , Meningitis, Meningococcal/immunology , Meningitis, Meningococcal/microbiology , Middle Aged , Neisseria meningitidis , Otitis Media/immunology , Pneumonia/immunology , Purpura Fulminans/immunology , Retrospective Studies , Sepsis/immunology , Shock, Septic/immunology , Young AdultSubject(s)
Anemia, Aplastic , HIV Infections , Adult , Aged , Allografts , Anemia, Aplastic/etiology , Anemia, Aplastic/therapy , Europe , Female , HIV Infections/complications , HIV Infections/therapy , Hematopoietic Stem Cell Transplantation , Humans , Male , Middle Aged , Retrospective Studies , Societies, MedicalABSTRACT
BACKGROUND: Among patients with thrombotic microangiopathies, acute kidney injury (AKI) is the hallmark of hemolytic uremic syndrome (HUS) and is largely underestimated in patients with thrombotic thrombocytopenic purpura (TTP). OBJECTIVE: We sought to report AKI features and outcomes in patients with TTP. METHODS: We conducted a retrospective study of 92 patients with TTP assessed by low ADAMTS13 activity (< 10%) between 2001 and 2013. A logistic regression identified variables independently associated with AKI. RESULTS: Among the 92 patients, 54 (58.7%) presented with AKI, including 25 (46.3%) with stage 3 AKI. Fourteen (27.4%) patients had a nephrotic-range proteinuria and 21 (45.6%) had hemoglobinuria. Hematuria and leucocyturia were detected in 19 (41.3%) and 16 patients (36.4%), respectively. Renal replacement therapy (RRT) was required in 14 patients (25.9%). Six months after TTP remission, RRT-free patients had median (IQR) MDRD (Modification of Diet in Renal Disease formula estimating the glomerular filtration rate) of 93 mL min(-1) per 1.73 m(2) (68.8-110) and three patients required long-term dialysis. Mild or moderate chronic renal disease occurred in 23/54 (42.6%) AKI patients. By multivariate analysis, serum level of complement component 3 at admission was the only factor independently associated with AKI (OR per 0.25 unit decrease of C3, 0.85; CI, 1.82-8.33; P = 0.001). CONCLUSIONS: In patients with TTP, AKI is present in more than half the patients, and half of those will have lasting renal effects. Further studies to better understand the pathophysiology of renal involvement in patients with TTP and to identify a subset of patients with TTP syndrome overlapping HUS are warranted.
Subject(s)
ADAM Proteins/blood , Acute Kidney Injury/epidemiology , Purpura, Thrombotic Thrombocytopenic/enzymology , ADAMTS13 Protein , Acute Kidney Injury/diagnosis , Acute Kidney Injury/physiopathology , Acute Kidney Injury/therapy , Adult , Biomarkers/blood , Chi-Square Distribution , Complement C3/analysis , Down-Regulation , Female , Glomerular Filtration Rate , Humans , Incidence , Kidney/physiopathology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Paris/epidemiology , Prevalence , Purpura, Thrombotic Thrombocytopenic/blood , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/epidemiology , Recovery of Function , Renal Replacement Therapy , Retrospective Studies , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
We report two patients with diabetes in whom acute renal failure requiring hemodialysis occurred while on treatment with glucagon-like peptide-1 receptor agonists. We discuss the mechanisms of this complication and the potential for its prevention.
Subject(s)
Acute Kidney Injury/chemically induced , Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide 1/adverse effects , Hypoglycemic Agents/adverse effects , Receptors, Glucagon/agonists , Acute Kidney Injury/therapy , Aged , Female , Glucagon-Like Peptide-1 Receptor , Humans , Male , Middle Aged , Prognosis , Renal DialysisABSTRACT
Treatment of common variable immunodeficiency disorders (CVID) is based on replacement therapy using intravenous (i.v.) or subcutaneous (s.c.) immunoglobulin (Ig)G. Interindividual variation of IgG dose is common. A total of 380 CVID patients on stable IgG replacement from two prospective cohorts were analysed. An 'efficiency' index was defined as the ratio of serum IgG trough level minus IgG residual to the average weekly dose of IgG infusion. A reduced efficiency of IgG was associated independently with the i.v. route (P < 0·001) and with the presence of at least one CVID disease-related phenotype (lymphoproliferation, autoimmune cytopenia or enteropathy) (P < 0·001). High IgG efficiency was noted in patients homozygotes for the variable number tandem repeat (VNTR) 3/3 polymorphism of the neonatal Fc receptor gene [IgG Fc fragment receptor transporter alpha chain (FCGRT)] promoter, and this was particularly significant in patients treated with IVIG (P < 0.01). In a multivariate analysis, FCGRT VNTR 3/3 genotype (P = 0·008) and high serum albumin (P < 0·001) were associated independently with increased efficiency of i.v. Ig.
Subject(s)
Biomarkers, Pharmacological , Common Variable Immunodeficiency/drug therapy , Histocompatibility Antigens Class I/genetics , Immunoglobulins, Intravenous/administration & dosage , Receptors, Fc/genetics , Adult , Cohort Studies , Common Variable Immunodeficiency/immunology , Female , Humans , Immunoglobulins, Intravenous/adverse effects , Injections, Subcutaneous , Male , Middle Aged , Minisatellite Repeats/genetics , Phenotype , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Prospective Studies , Transcriptional Activation/genetics , Treatment OutcomeABSTRACT
BACKGROUND: Castleman disease (CD) in the context of human immunodeficiency virus (HIV) infection is well described. It is almost always multicentric (MCD) and linked to human herpesvirus 8 (HHV-8). There are limited published data surrounding HHV-8-related CD among HIV-negative patients. METHODS: From January 1995 through June 2012, we identified in a single center 18 HIV-seronegative patients with HHV-8-related CD. We report on their clinical, pathological, and laboratory features. RESULTS: All cases were multicentric. Patients were aged 42-83 years and were referred with a relapsing remitting syndrome of fever (94%), constitutional symptoms (100%), peripheral lymphadenopathy (100%), splenomegaly (72%), hepatomegaly (50%), and edema (28%). Kaposi sarcoma was observed in 9 cases. Anemia and serum markers of inflammation were present in all cases. Polymerase chain reaction for HHV-8 DNA was positive on blood samples in all cases, whereas only 12 of 16 patients tested had positive HHV-8 serology at diagnosis. All cases showed the classic histological features of MCD, and LANA-1 immunostaining identified HHV-8-infected plasmablasts in 16 of 16 tested cases. Reactive hemophagocytic syndrome (44%), autoimmune hemolytic anemia (33%), and lymphoma (22%) were the commonest associated complications. Remission was obtained with etoposide in 13 of 15 cases. Rituximab allowed prolonged remission off therapy in 10 cases. Death occurred in 3 patients not treated with rituximab. These features were similar to those described in HIV-positive HHV-8-related MCD. Comparison between these 18 cases and 12 HIV-negative HHV-8-unrelated MCD cases showed marked discrepancies. CONCLUSIONS: HHV-8-associated MCD may be considered as a single clinicopathological entity regardless of HIV status.
Subject(s)
Castleman Disease/etiology , Castleman Disease/pathology , Herpesviridae Infections/complications , Herpesviridae Infections/pathology , Herpesvirus 8, Human/isolation & purification , Adult , Aged , Aged, 80 and over , Anemia , Castleman Disease/virology , DNA, Viral/genetics , DNA, Viral/isolation & purification , Female , HIV , Herpesviridae Infections/virology , Herpesvirus 8, Human/genetics , Humans , Male , Middle Aged , Polymerase Chain ReactionABSTRACT
Microsporidiosis first came to prominence as an opportunistic infection in patients with acquired immunodeficiency syndrome. Microsporidia are now emerging pathogens responsible for severe diarrhea during solid organ transplantation. Two main clinical entities can be identified: infection by Enterocytozoon bieneusi, causing diarrhea with limited treatment options; and infection by Encephalitozoon intestinalis, which may disseminate and usually responds to albendazole treatment. We describe here 2 cases of microsporidiosis caused by E. bieneusi in a renal and a liver transplant recipient, respectively, in whom complete clinical efficacy of a short course of fumagillin therapy was obtained. Long-term microbiological eradication was assessed using classical methods and monitored using a real-time quantitative polymerase chain reaction-based method. Both patients experienced drug-induced thrombocytopenia, which resolved after withdrawal of the treatment. We also review the 18 other previously reported cases of microsporidiosis in transplant recipients. In case of persistent diarrhea in solid organ transplant patients, microsporidiosis should be considered. Based on the present experience, treating E. bieneusi infection with 7 days of fumagillin therapy is adequate to eradicate E. bieneusi in this context.
Subject(s)
Cyclohexanes/therapeutic use , Enterocytozoon/drug effects , Fatty Acids, Unsaturated/therapeutic use , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Microsporidiosis/drug therapy , Animals , Humans , Male , Microsporidiosis/microbiology , Middle Aged , Sesquiterpenes/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Herpes simplex virus hepatitis is a rare complication associated with a poor prognosis and a high mortality rate. It mainly affects adults with impaired cell-mediated immunity. Mucocutaneous involvement is seen in only 57% to 70% of patients and the clinical aspects of the lesions may sometimes be misleading. Here we report a new case that developed during primary HSV-2 infection in a patient with systemic lupus erythematosus. CASE REPORT: A 57 year-old man with systemic lupus erythematosus treated with oral prednisone presented a disseminated varicella-like eruption with acute liver failure related to primary genital HSV-2 infection. Type-specific HSV deoxyribonucleic acid amplification by polymerase chain reaction on serum and oral lesion samples revealed type 2 HSV. Dramatic improvement was observed with parenteral acyclovir. DISCUSSION: Hepatitis due to HSV is a rare but potentially fatal disorder chiefly affecting adults with impaired immune systems. In this case, HSV affects the liver during primary or recurrent infection. If initiated quickly, parenteral acyclovir can cure hepatitis, which means that this diagnosis must be considered in both immunocompromised and immunocompetent patients with high fever, leucopoenia and marked elevation of aminotransferase levels. Mucocutaneous signs are present in only 57 to 70% of cases. Careful physical examination to detect herpes lesions should be done in all cases of acute liver failure. HSV viremia testing may confirm the diagnosis by non-invasive means. Patients with systemic lupus erythematosus are at increased risk for infection due to immunosuppressive drugs, but also to numerous intrinsic immunologic abnormalities such as a recently reported deficit in NK cells and plasmacytoid dendritic cells.
Subject(s)
Hepatitis/etiology , Herpes Simplex/complications , Herpesvirus 2, Human , Lupus Erythematosus, Systemic/complications , Acute Disease , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Hepatitis/pathology , Herpes Simplex/pathology , Herpesvirus 2, Human/genetics , Herpesvirus 2, Human/isolation & purification , Humans , Lupus Erythematosus, Systemic/pathology , Male , Middle Aged , Penile Diseases/virologyABSTRACT
INTRODUCTION: Leptospirosis is an anthropozoonosis, which affect 100000 people by year worldwide. CASE REPORT: Leptospirosis and IgA deficiency were revealed in a young man by acute anterior uveitis, after canyoning practice in the French West Indies. DISCUSSION: Uveitis should be added to the ocular phenotype of leptospirosis.